35 results about "Peripheral Artery Diseases" patented technology

The invention discloses a human body peripheral blood vessel photoacoustic three-dimensional imaging device and an imaging method thereof, and belongs to the field of blood vessel imaging. Through high resolution and functional monitoring capability of photoacoustic imaging, detailed blood vessel structure and blood flow dynamic information are provided, and early recognition and treatment effect evaluation of common lesions such as diabetic foot and peripheral artery diseases are promoted; meanwhile, a mechanical system is adopted, so that the detection front end with relatively high quality can be borne, and stable operation is realized, and a relatively good photoacoustic imaging result is obtained; the system has a highly stable accurate scanning imaging mode, and is convenient for multiple imaging modes of clinical application; through the arrangement of the imaging water tank and the lifting structure of the imaging water tank, switching of imaging modes in a limited space can be ensured, so that the device can be suitable for the layout of a portal type three-dimensional moving device. The system is expected to promote the portability of equipment, reduce the research and development cost of the equipment, be widely applied to clinical practice and community medical treatment, and improve the disease management level.

The invention provides an application of a super enhancer inhibitor JQ-1 in preparation of peripheral artery disease related drugs, relates to the technical field of biomedicine, and discloses a core effect of the super enhancer inhibitor JQ-1 in peripheral artery disease ischemia repair. The traditional Chinese medicine composition can significantly accelerate blood flow recovery of ischemic limbs, up-regulate mRNA and protein expression of a vascular marker CD31 in gastrocnemius muscle tissues, effectively increase vascular density and promote angiogenesis. Aiming at the defects of the existing treatment means in the aspect of ischemic tissue angiogenesis, the application provides a brand new molecular targeted treatment scheme for high-risk groups such as patients with diabetes-related peripheral artery diseases, and can significantly reduce the risk of lower limb amputation and the incidence rate of related cardiovascular adverse events such as coronary heart disease and stroke; the technical blank of specific targeted therapy of peripheral artery diseases is filled, a solid scientific basis and a key direction are provided for research and development of novel drugs, and the specific targeted therapy method has extremely high clinical application value and wide research and development prospects.

The present invention relates to a weighing scale (100) for monitoring biometric data of a user (180). The weighing scale (100) comprises a first set and a second set of multiple electrodes disposed on one or more handles (120) for making contact with a first hand and a second hand of the user (180). The weighing scale (100) further comprises a base (140) for supporting the user (180) and determining a weight of the user (180). A first portion of a top surface of the base (140) comprises a third set of multiple electrodes for making contact with a first foot of the user (180) and a second portion of the top surface of the base (140) comprises a fourth set of multiple electrodes for making contact with a second foot of the user (180). The weighing scale (100) further comprises processing circuitry for obtaining a plurality of biometric signals and determining a pulse wave velocity (PWV) of the first hand and the second hand and the first foot and the second foot of the user (180) based on the plurality of biometric signals to estimate a peripheral arterial disease (PAD) risk of the user (180).

The subject invention pertains to a novel method for treating Peripheral Arterial Disease (PAD) by leveraging the angiogenic potential oftype 2 cytokines IL-4 and IL-13 to enhance the efficacy of induced pluripotent stem cell-derived endothelial cells (iPSC-ECs) and induced endothelial cells derived from fibroblasts (iECs). This present invention aims at enhancing the muscle regeneration and revascularization for obese and diabetes individuals.

A siRNA for inhibiting LPA gene expression, and a modifier and the use thereof, belonging to the field of biomedicine. Provided are a double-stranded RNA molecule targeting an LPA gene, and a modifier thereof. Both in vivo and in vitro experiments show that the provided double-stranded RNA molecule can effectively inhibit LPA gene expression, and can be used for preventing and / or treating Lp(a)-related diseases, such as thrombosis, atherosclerotic thrombosis, coronary artery disease, ischemic strokes, aortic valve stenosis, heart failure, atrial fibrillation, and peripheral artery disease.

The present invention provides a closed loop generation and / or infusion system comprising a radionuclide generator, an activity detector, a controller, a dose calibrator, a pump, eluant source and an automated elution system controlled by software and hardware for generation and infusion of a radionuclide for administering a dose of generated radionuclide into a subject for diagnosing a peripheral arterial disease in a subject suffering from or suspected of suffering from peripheral arterial disease and / or metabolic disease via Positron Emitting Tomography (PET) or Single-photon emission computed tomography (SPECT) imaging technologies. More particularly, the present invention provides methods of determining whether a subject is suffering or at a risk of developing a peripheral arterial disease by performing quantitative assessment of blood flow in lower extremities or limbs of the subject; wherein the quantitative assessment is performed by analyzing one or more images and providing a severity score; and wherein the analysis of the one or more images is performed by using an automated system.

The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension or Alzheimer disease. The present invention relates to a compound of the formula [I-a] or the formula [II], or a pharmaceutically acceptable salt thereof:wherein each symbol means the same as that described in the specification.

Methods and systems are disclosed for using medical imaging data to diagnose peripheral arterial disease. In a method, a plurality of artificial intelligence based neural network models are trained on medical imaging data of a large population of anonymous patients after labeling and structuring the data for training and testing purposes. Medical imaging data of a known patient is then processed by the plurality of pre-trained artificial intelligence based neural network models to diagnose peripheral arterial disease. A rule-based algorithm integrates the predictions made by the pre-trained neural network models. An inference engine analyzes the integrated predictions data for the known patient, detects any anomalies in the pixel intensities present in each medical image, and performs volumetric calculations. A report generation engine generates medical reports for the known patient. A visualization tool enables a clinician to display and view the results of the diagnoses superimposed on medical images.

Disclosed herein is a further medical use of semaglutide, namely semaglutide in the treatment of intermittent claudication in a human subject with diabetes and peripheral arterial disease. Semaglutide is shown to have a positive impact on symptoms of intermittent claudication and therefore the functional limb capacity and quality of life of patients with type 2 diabetes and peripheral arterial disease.

RNA interference (RNAi) agents for inhibiting the expression of Factor XI (FXI) are provided, as are pharmaceutical compositions comprising one or more FXI RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the FXI RNAi agent(s) to liver cells in vivo provides for inhibition of FXI gene expression and can provide for treatment of myocardial infarction, atrial fibrillation (AFib), deep vein thrombosis, pulmonary embolism, ischemic stroke, transient ischemic attack, retinal artery occlusion, mesenteric ischemia, renal vein thrombosis, cerebral venous sinus thrombosis, venous thromboembolism due to deep vein thrombosis, and peripheral artery disease, as well as diseases and disorders associated with angioedema, thrombosis, and / or coagulation.

The application discloses a kind of human peripheral blood vessel photoacoustic three-dimensional imaging device and imaging method thereof, belong to blood vessel imaging field.The application provides detailed blood vessel structure and blood flow dynamic information by high resolution and functional monitoring ability of photoacoustic imaging, promote early identification and treatment effect evaluation to common pathological changes such as diabetic foot and peripheral arterial disease;Meanwhile, the application adopts mechanical system, and the detection front end of higher quality can be carried and stably operated, to obtain better photoacoustic imaging result;The application has highly stable precision scanning imaging mode, and various imaging modes are convenient for clinical application;Through the arrangement of imaging tank and its lifting structure, it is ensured that the switching of imaging mode can be applied in limited space, so as to be suitable for gantry type three-dimensional mobile device layout.The application is expected to promote the portability of equipment, reduce equipment development cost, be widely applied in clinical practice and community medical treatment, and improve disease management level.

Disclosed herein is a further medical use of semaglutide, namely semaglutide in the treatment of intermittent claudication in a human subject with diabetes and peripheral arterial disease. Semaglutide is shown to have a positive impact on symptoms of intermittent claudication and therefore the functional limb capacity and quality of life of patients with type 2 diabetes and peripheral arterial disease.

The present disclosure provides pharmaceutical compositions comprising an anticoagulant and pyruvic acid. Also provided are dosage forms comprising the pharmaceutical composition and methods for treating a thromboembolic disorder in a patient in need thereof, reducing the reoccurrence of a deep vein thrombosis or a pulmonary embolism in a patient in need thereof, preventing a venous thromboembolism (VTE) in an acutely ill patient, reducing the risk of a major cardiovascular event in a patient with coronary artery disease in a patient in need thereof, method for reducing the risk of a major thrombotic vascular event in a patient with peripheral artery disease (PAD), treating VTE or reducing the risk of reoccurrence of VTE in a pediatric patient in need thereof, thromboprophylaxis in a patient with congenital heart disease after a Fontan procedure, treating atherosclerosis, myocardial infarct, pulmonary embolism or deep venous thrombosis in a patient in need thereof, or preventing one or more thromboembolic or hemorrhagic events in a patient with atrial fibrillation by comprising administering the pharmaceutical composition or transdermal patch described herein to the patient.

RNA interference (RNAi) agents for inhibiting the expression of Factor XI (FXI) are provided, as are pharmaceutical compositions comprising one or more FXI RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the FXI RNAi agent(s) to liver cells in vivo provides for inhibition of FXI gene expression and can provide for treatment of myocardial infarction, atrial fibrillation (AFib), deep vein thrombosis, pulmonary embolism, ischemic stroke, transient ischemic attack, retinal artery occlusion, mesenteric ischemia, renal vein thrombosis, cerebral venous sinus thrombosis, venous thromboembolism due to deep vein thrombosis, and peripheral artery disease, as well as diseases and disorders associated with angioedema, thrombosis, and / or coagulation.

The present application relates to a DNA drug, a gene targeting delivery system and its application in the treatment of lower extremity peripheral arterial disease. Specifically, the present application relates to a microcrystalline nanocarbon targeted drug delivery system and a plasmid containing human interleukin-4 gene loaded thereon. The delivery system comprises a matrix microcrystalline nanocarbon, and folate, polyethyleneimine and polyethylene glycol modified on the surface thereof. The matrix microcrystalline nanocarbon has a size of 5-20 nanometers, a crystallinity of >80%, a rich mesoporous structure, a high specific surface area and good biocompatibility. The present application also provides a preparation method of the system, which comprises the steps of synthesizing a matrix by pulse modulation radio frequency plasma enhanced chemical vapor deposition, surface functionalization modification and plasmid loading. After injection into the lower extremity muscle, the system can actively target the macrophages in the ischemic site, realize long-term expression of the IL-4 gene at the lesion site. It can effectively promote stable, mature functional angiogenesis by inducing macrophages to polarize to the repair M2 phenotype and regulating the OSM / GSNOR / ENG signal axis, thereby improving limb ischemia. The present application has important application value in the field of gene therapy for ischemic diseases, especially peripheral arterial disease and severe limb ischemia.

The present invention discloses a compound represented by formula (I), its stereoisomer, or pharmaceutically acceptable salt, and key intermediates. The present invention further provides the use of the compound, its stereoisomer, or pharmaceutically acceptable salt in the manufacture of a medicament for treating and / or preventing a disease associated with the FXIa receptor, particularly in the manufacture of a medicament for treating and / or preventing cerebrovascular arterial disease and / or peripheral arterial disease. TIFF2025542415000028.tif41165

Early diagnosis of cardiovascular diseases can potentially cure subjects and save innumerable lives. Diagnosis and treatment of subjects at early stages by cardiologists remain a challenge. Here, the inventors have measured baseline sTREM-1 (triggering receptor expressed on myeloid cells-1) in 10,000 initially healthy participants without prevalent cardiovascular disease (CVD) from the Paris Prospective Study 3 (PPS3). They have quantified the association and predictive value of baseline sTREM-1 for incident CVD events over 10 years of follow-up. The analysis reveals strong, significant and independent association with incident CVD events combined and its subtypes (coronary heart disease, stroke, peripheral artery diseases, and heart failure). Furthermore, adding sTREM-1 to existing risk prediction algorithms such as SCORE2 or the US pooled risk equation improved the discrimination capacity of these models in a significant and more importantly in a clinically meaningful manner, including among those at moderate CVD risk. Furthermore, the inventors have examined CVD events such as aneurysm, arrythmias and thromboembolic events. Given the ongoing development of pharmacological molecules blocking blood sTREM-1, the inventors believe these findings support future intervention trials testing to which extent sTREM-1 could be a relevant target for the primary prevention of CVD in the general population.

Among the various aspects of the present disclosure is the provision of a systems and methods for peripheral arterial disease (PAD), predicting PAD patient prognosis, and selecting appropriate treatments for PAD patients based on patient clinical data using machine learning methods.

The plantar surface of the patient is in contact with the receiving area of the device body, causing a set of temperature sensors to produce a current set of temperature values. Four or more earlier sets of temperature values produced earlier in time for the plantar surface of the patient are accessed. Next, after setting a normalization reference for the earlier sets of temperature values and the current set of temperature values to produce normalized data, the normalized data is translated into model information representative of PDN or PAD progression. The model information is used to determine a trajectory of the PDN or PAD of the patient.

The invention provides a nucleic acid molecule for treating peripheral artery diseases of lower limbs and encoding multiple angiogenesis factors, a pharmaceutical composition and application of the nucleic acid molecule. Compared with the prior art, the pharmaceutical composition for treating the peripheral artery diseases of the lower limbs, provided by the invention, can remarkably promote angiogenesis of the lower limbs and improve ischemia of the lower limbs.

A preparation comprising the YEL002 compound as an active ingredient for the prevention or treatment of one or more diseases, and methods of using such preparations. The preparations may be a sublingual pill, an injection, dissolved in liquid, dissolved in oil, or any other preparation. The conditions or diseases indicated may be poisoning, radiation poisoning, chemotherapy poisoning, poor vision, peripheral artery disease, smoker's leg, diabetic feet, periodontal disease, varicose or spider veins, blood clots, COVID-19, long COVID, liver disease, symptoms caused by chemotherapy or radiation therapy, hair loss, cancer, inflammation-caused or inflammation-related diseases, autoimmune diseases, infections, and headaches including migraines.

A cell product may be used for treating a peripheral blood flow disorder, and the cell product may include an SSEA-3-positive pluripotent stem cells (Muse cells) derived from a mesenchymal tissue in a living body or a cultured mesenchymal cell. The peripheral blood flow disorder is preferably a peripheral arterial disease, more preferably chronic arterial obstruction in a limb.

Provided are a nucleic acid molecule encoding a plurality of angiogenesis factors and a pharmaceutical composition for the treatment of peripheral arterial disease in the lower limb, and use thereof. Relative to the prior art, the pharmaceutical composition for the treatment of peripheral arterial disease in the lower limb can significantly promote lower limb angiogenesis and improve lower limb ischemia.

Described herein are compositions (e.g., an inhibitory nucleic acid molecule) for reducing expression of small EDRK-rich factor 2 (SERF2) and methods thereof for (i) treating cardiovascular disease (e.g., PAD, CAD, heart failure, cardiomyopathy, or stroke) in a subject; (ii) treating or reducing the likelihood of CTLI in a subject; (iii) alleviating chronic ischemic rest pain in a subject having CTLI; and / or (iv) promoting angiogenesis in a subject (e.g., a subject having or at risk of developing a cardiovascular disease). The inhibitory nucleic acid molecule may be a small interfering RNA (siRNA), a double-stranded RNA (dsRNA), an anti-sense oligonucleotide (ASO), a microRNA (miRNA), a short hairpin RNA (shRNA), or a gapmeR described herein, or a composition (e.g., pharmaceutical composition) thereof.

Described herein are compositions and methods for treating peripheral artery diseases, including a composition comprising a nanoparticle defining an interior volume and an exterior surface; a payload disposed within the interior volume of the nanoparticle; and a cellular membrane coating disposed on or encapsulating the exterior surface of the nanoparticle; wherein the cellular membrane coating comprises an ICAM1 binding ligand.

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of AGT RNA in a cell or subject, and in certain instances reducing the amount of AGT in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a cardiovascular disease. Such compound and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a RAAS pathway-related disease or disorder. Such symptoms and hallmarks include hypertension, chronic kidney disease, stroke, myocardial infarction, heart failure, valvular heart disease, aneurysms of the blood vessels, peripheral artery disease, and organ damage. Such cardiovascular diseases include hypertension, resistant hypertension, Marfan syndrome, and heart failure.

In some aspects, the present disclosure provides compounds of the formulae:wherein the variables are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, the compounds or compositions of the present disclosure may be used for the treatment of diseases or disorders, such as eye diseases and peripheral arterial diseases such as hind limb ischemia.

The invention discloses an application of 17 alpha-estradiol in diseases related to vascular aging. The 17alpha-estradiol disclosed by the invention is capable of remarkably improving the vascular endothelial cell activity of the aged male animal and effectively improving the aging function of the aged male animal for the first time. The discovery shows that 17alpha-estradiol can directly act on endothelial dysfunction, which is a core link of vascular senescence, and provides a treatment choice with a brand new mechanism for preventing and treating vascular senescence related diseases such as arteriosclerosis, senile hypertension, coronary heart disease, ischemic cerebral apoplexy, vascular cognitive impairment and peripheral artery disease; due to the effectiveness in an old male animal model, the compound is particularly suitable for blood vessel health maintenance and disease prevention and treatment of middle-aged and old men, and the aim of delaying blood vessel aging is expected to be achieved.

This invention relates to substituted pyrazolopiperidine carboxylic acids, their salts and methods of preparation thereof, and also to their use in the preparation of medicaments for the treatment and / or prevention of diseases, particularly cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral artery disease (PAD, PAOD), cardiorenal and renal diseases, preferably chronic kidney disease and diabetic kidney disease (CKD and DKD), cardiopulmonary and pulmonary diseases, preferably pulmonary hypertension (PH) and other diseases, preferably neurodegenerative diseases and different forms of dementia, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), and wound healing disorders such as diabetic foot ulcers (DFU).